Published in Nature on May 31, 2001
Genetic Markers as Predictors of Phenotypes in Pediatric Onset Crohn's Disease | NCT00783575
Safety and Efficacy of AST-120 in Mild to Moderate Crohn's Patients With Fistulas | NCT00321412
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature (2007) 144.95
A haplotype map of the human genome. Nature (2005) 105.70
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet (2008) 30.20
A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science (2006) 27.49
Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet (2007) 19.08
Genotype imputation. Annu Rev Genomics Hum Genet (2009) 18.64
Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat Genet (2007) 13.74
Interactions between the microbiota and the immune system. Science (2012) 10.45
Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet (2001) 9.34
Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J Exp Med (2006) 7.76
Genome-wide analysis of NBS-LRR-encoding genes in Arabidopsis. Plant Cell (2003) 7.66
The human microbiome: at the interface of health and disease. Nat Rev Genet (2012) 7.54
Shifting paradigm of association studies: value of rare single-nucleotide polymorphisms. Am J Hum Genet (2008) 7.36
Inflammatory bowel disease. Annu Rev Immunol (2010) 7.10
The fundamental basis of inflammatory bowel disease. J Clin Invest (2007) 6.84
Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. Am J Hum Genet (2005) 6.61
Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). Annu Rev Immunol (2009) 5.91
Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nat Genet (2011) 5.58
NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med (2009) 5.43
Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest (2004) 5.39
Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut (2004) 5.32
CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet (2002) 5.31
The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity (2010) 5.12
A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. Am J Hum Genet (2006) 5.10
The NLR gene family: a standard nomenclature. Immunity (2008) 4.77
Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev (2009) 4.55
Innate and adaptive immunity cooperate flexibly to maintain host-microbiota mutualism. Science (2009) 4.45
Reciprocal interactions of the intestinal microbiota and immune system. Nature (2012) 4.42
NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut (2004) 4.39
The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med (2010) 4.37
Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immunol (2013) 4.34
Common disorders are quantitative traits. Nat Rev Genet (2009) 4.34
Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut (2001) 4.23
Rational inferences about departures from Hardy-Weinberg equilibrium. Am J Hum Genet (2005) 4.15
Integrative annotation of chromatin elements from ENCODE data. Nucleic Acids Res (2012) 3.80
The microbiome in infectious disease and inflammation. Annu Rev Immunol (2012) 3.76
Joint modeling of linkage and association: identifying SNPs responsible for a linkage signal. Am J Hum Genet (2005) 3.62
The death domain superfamily in intracellular signaling of apoptosis and inflammation. Annu Rev Immunol (2007) 3.59
Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease. J Exp Med (2009) 3.58
Nod2 is required for the regulation of commensal microbiota in the intestine. Proc Natl Acad Sci U S A (2009) 3.58
European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut (2006) 3.57
Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology (2010) 3.51
STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity. Proc Natl Acad Sci U S A (2003) 3.46
Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov (2010) 3.35
Epithelial antimicrobial defence of the skin and intestine. Nat Rev Immunol (2012) 3.21
IL-1 beta -converting enzyme (caspase-1) in intestinal inflammation. Proc Natl Acad Sci U S A (2001) 3.21
Function of Nod-like receptors in microbial recognition and host defense. Immunol Rev (2009) 3.20
The ubiquitin-editing enzyme A20 restricts nucleotide-binding oligomerization domain containing 2-triggered signals. Immunity (2008) 3.19
Diverse genome-wide association studies associate the IL12/IL23 pathway with Crohn Disease. Am J Hum Genet (2009) 3.19
Genetic analysis of innate immunity in Crohn's disease and ulcerative colitis identifies two susceptibility loci harboring CARD9 and IL18RAP. Am J Hum Genet (2008) 3.11
CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest (2003) 2.97
IL23R variation determines susceptibility but not disease phenotype in inflammatory bowel disease. Gastroenterology (2007) 2.97
NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. J Clin Invest (2013) 2.96
Autoimmune diseases: insights from genome-wide association studies. Hum Mol Genet (2008) 2.94
Culture-independent analyses of temporal variation of the dominant fecal microbiota and targeted bacterial subgroups in Crohn's disease. J Clin Microbiol (2006) 2.93
Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis. J Clin Invest (2008) 2.88
Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium. Am J Epidemiol (2010) 2.86
Intestinal bacteria and the regulation of immune cell homeostasis. Annu Rev Immunol (2010) 2.85
Genetic insights into common pathways and complex relationships among immune-mediated diseases. Nat Rev Genet (2013) 2.85
A20: central gatekeeper in inflammation and immunity. J Biol Chem (2008) 2.83
Regulatory regions and critical residues of NOD2 involved in muramyl dipeptide recognition. EMBO J (2004) 2.81
Expression of NOD2 in Paneth cells: a possible link to Crohn's ileitis. Gut (2003) 2.74
The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology (2014) 2.73
NLRP12 attenuates colon inflammation by maintaining colonic microbial diversity and promoting protective commensal bacterial growth. Nat Immunol (2017) 2.69
Intestinal barrier function: molecular regulation and disease pathogenesis. J Allergy Clin Immunol (2009) 2.63
Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. Inflamm Bowel Dis (2010) 2.62
Inflammasomes: too big to miss. J Clin Invest (2009) 2.51
Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn's disease. Hum Mol Genet (2010) 2.51
Recognition of Staphylococcus aureus by the innate immune system. Clin Microbiol Rev (2005) 2.50
Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis (2009) 2.49
Transient inability to manage proteobacteria promotes chronic gut inflammation in TLR5-deficient mice. Cell Host Microbe (2012) 2.48
The Nod2 sensor promotes intestinal pathogen eradication via the chemokine CCL2-dependent recruitment of inflammatory monocytes. Immunity (2011) 2.47
IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism. Proc Natl Acad Sci U S A (2005) 2.46
CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease. J Clin Invest (2007) 2.44
A proposed classification of the immunological diseases. PLoS Med (2006) 2.43
Recent advances in the genetics of autoimmune disease. Annu Rev Immunol (2009) 2.41
New mutations of CIAS1 that are responsible for Muckle-Wells syndrome and familial cold urticaria: a novel mutation underlies both syndromes. Am J Hum Genet (2002) 2.39
Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol (2007) 2.36
Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest (2004) 2.34
Predominant role of host genetics in controlling the composition of gut microbiota. PLoS One (2008) 2.33
Familial cold autoinflammatory syndrome: phenotype and genotype of an autosomal dominant periodic fever. J Allergy Clin Immunol (2001) 2.33
The human intestinal microbiome: a new frontier of human biology. DNA Res (2009) 2.30
Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev (2002) 2.29
Gene-centric association mapping of chromosome 3p implicates MST1 in IBD pathogenesis. Mucosal Immunol (2008) 2.28
Heterotypic interactions among NACHT domains: implications for regulation of innate immune responses. Biochem J (2004) 2.23
Crohn's disease-associated adherent-invasive E. coli are selectively favoured by impaired autophagy to replicate intracellularly. Cell Microbiol (2009) 2.23
Gene-microbiota interactions contribute to the pathogenesis of inflammatory bowel disease. Science (2016) 2.22
The CATERPILLER protein monarch-1 is an antagonist of toll-like receptor-, tumor necrosis factor alpha-, and Mycobacterium tuberculosis-induced pro-inflammatory signals. J Biol Chem (2005) 2.21
Common pathways in Crohn's disease and other inflammatory diseases revealed by genomics. Gut (2007) 2.20
Chronic stimulation of Nod2 mediates tolerance to bacterial products. Proc Natl Acad Sci U S A (2007) 2.20
SecA2-dependent secretion of autolytic enzymes promotes Listeria monocytogenes pathogenesis. Proc Natl Acad Sci U S A (2003) 2.18
The NOD-like receptor NLRP12 attenuates colon inflammation and tumorigenesis. Cancer Cell (2011) 2.18
Genetic basis for increased intestinal permeability in families with Crohn's disease: role of CARD15 3020insC mutation? Gut (2005) 2.17
Autophagy and human diseases. Cell Res (2013) 2.17
Alterations in intestinal permeability. Gut (2006) 2.17
Investigation of Crohn's disease risk loci in ulcerative colitis further defines their molecular relationship. Gastroenterology (2008) 2.17
A novel NOD2/CARD15 haplotype conferring risk for Crohn disease in Ashkenazi Jews. Am J Hum Genet (2003) 2.17
Effects of family history on inflammatory bowel disease characteristics in Japanese patients. J Gastroenterol (2012) 2.17
Gene-environment interaction modulated by allelic heterogeneity in inflammatory diseases. Proc Natl Acad Sci U S A (2003) 2.16
Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature (1990) 14.46
bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell (1993) 14.39
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med (1997) 10.67
Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ (2008) 10.45
Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science (1997) 9.58
Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ (2011) 9.44
Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity (1999) 7.78
A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis (2000) 6.90
Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem (2000) 6.54
Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med (1999) 6.24
Negative regulation of the forkhead transcription factor FKHR by Akt. J Biol Chem (1999) 5.66
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut (2007) 4.21
Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr (1991) 4.11
Laparoscopic colectomy. Ann Surg (1992) 4.02
Loci on chromosomes 2 (NIDDM1) and 15 interact to increase susceptibility to diabetes in Mexican Americans. Nat Genet (1999) 3.95
Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2001) 3.85
Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ (2009) 3.44
An induced proximity model for NF-kappa B activation in the Nod1/RICK and RIP signaling pathways. J Biol Chem (2000) 3.44
Preliminary evidence for genetic anticipation in Crohn's disease. Lancet (1996) 3.32
Human Nod1 confers responsiveness to bacterial lipopolysaccharides. J Biol Chem (2000) 3.23
Caspases: the proteases of the apoptotic pathway. Oncogene (1998) 3.11
Lymphocytic ("microscopic") colitis: a comparative histopathologic study with particular reference to collagenous colitis. Hum Pathol (1989) 3.02
Evidence that BCL-2 represses apoptosis by regulating endoplasmic reticulum-associated Ca2+ fluxes. Proc Natl Acad Sci U S A (1994) 2.91
Intestinal ulceration--a complication of celiac disease. N Engl J Med (1967) 2.90
Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: evidence for epistasis between 1p and IBD1. Proc Natl Acad Sci U S A (1998) 2.88
Collagenous colitis with mucosal tears on endoscopic insufflation: a unique presentation. Gut (2002) 2.81
Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis (2001) 2.80
A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med (2000) 2.78
Expression of NOD2 in Paneth cells: a possible link to Crohn's ileitis. Gut (2003) 2.74
Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med (1999) 2.74
A randomized, controlled trial of a behavioral intervention to prevent sexually transmitted disease among minority women. N Engl J Med (1999) 2.70
Increased sensitivity to dextran sodium sulfate colitis in IRE1beta-deficient mice. J Clin Invest (2001) 2.67
Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. A case-control study. Gastroenterology (1989) 2.66
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology (1999) 2.62
Interaction and regulation of subcellular localization of CED-4 by CED-9. Science (1997) 2.58
Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease. Gastroenterology (1991) 2.55
Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis (1999) 2.55
Crohn's disease: influence of age at diagnosis on site and clinical type of disease. Gastroenterology (1996) 2.50
Bcl10 and MALT1, independent targets of chromosomal translocation in malt lymphoma, cooperate in a novel NF-kappa B signaling pathway. J Biol Chem (2001) 2.41
Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol (2001) 2.39
Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res (1997) 2.32
Gene-centric association mapping of chromosome 3p implicates MST1 in IBD pathogenesis. Mucosal Immunol (2008) 2.28
Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology (2000) 2.23
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology (2000) 2.21
Developmental regulation of the Bcl-2 protein and susceptibility to cell death in B lymphocytes. EMBO J (1994) 2.16
Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology (1999) 2.15
Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease. Aliment Pharmacol Ther (2013) 2.12
Bcl-XL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. Proc Natl Acad Sci U S A (1998) 2.04
Lower regional and temporal ultraviolet exposure is associated with increased rates and severity of inflammatory bowel disease hospitalisation. Aliment Pharmacol Ther (2014) 2.04
Setting the record straight. Tex Med (1998) 2.03
Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology (1993) 2.03
Increased interleukin-2 messenger RNA in the intestinal mucosal lesions of Crohn's disease but not ulcerative colitis. Gastroenterology (1992) 1.98
Chronic colitis with thickening of the subepithelial collagen layer (collagenous colitis): histopathologic findings in 15 patients. Hum Pathol (1987) 1.97
An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas. J Epidemiol Community Health (2003) 1.96
ARC, an inhibitor of apoptosis expressed in skeletal muscle and heart that interacts selectively with caspases. Proc Natl Acad Sci U S A (1998) 1.95
Control of the cell death pathway by Dapaf-1, a Drosophila Apaf-1/CED-4-related caspase activator. Mol Cell (1999) 1.91
Out of the shadows. Tex Med (1998) 1.91
Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol (1999) 1.90
Influenza A virus transfectants with chimeric hemagglutinins containing epitopes from different subtypes. J Virol (1992) 1.88
Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology (1999) 1.84
Cloning and sequencing of a rabbit cDNA encoding an intestinal and kidney-specific Na+/H+ exchanger isoform (NHE-3). J Biol Chem (1992) 1.81
Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther (2005) 1.79
Genomic organization, promoter region analysis, and chromosome localization of the mouse bcl-x gene. J Immunol (1997) 1.75
Surgical management of Crohn's disease. Influence of disease at margin of resection. Ann Surg (1980) 1.75
The NOD: a signaling module that regulates apoptosis and host defense against pathogens. Oncogene (2001) 1.74
Genome-wide association study of body mass index in 23 000 individuals with and without asthma. Clin Exp Allergy (2013) 1.74
American families with Crohn's disease have strong evidence for linkage to chromosome 16 but not chromosome 12. Gastroenterology (1998) 1.71
A racial difference in incidence of lactase deficiency. A survey of milk intolerance and lactase deficiency in healthy adult males. JAMA (1966) 1.70
Chimeric influenza virus induces neutralizing antibodies and cytotoxic T cells against human immunodeficiency virus type 1. J Virol (1993) 1.70
Pericholangitis and sclerosing cholangitis are risk factors for dysplasia and cancer in ulcerative colitis. Am J Gastroenterol (1993) 1.70
Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood (1996) 1.68
Neutrophil autoantibodies in ulcerative colitis: familial aggregation and genetic heterogeneity. Gastroenterology (1992) 1.67
Liver cells. Methods Enzymol (1979) 1.67
Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease. Gastroenterology (1988) 1.67
Lymphocytic (microscopic) colitis. Clinicopathologic study of 18 patients and comparison to collagenous colitis. Dig Dis Sci (1989) 1.65
Genetic variants in the region harbouring IL2/IL21 associated with ulcerative colitis. Gut (2009) 1.65
Hormonal control of rat liver regeneration. Gastroenterology (1979) 1.64
Erythropoietin can induce the expression of bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines. J Biol Chem (1999) 1.64
Genetic analysis of the VP1 region of human enterovirus 71 strains isolated in Korea during 2000. Arch Virol (2003) 1.64
Is lactobacillus GG helpful in children with Crohn's disease? Results of a preliminary, open-label study. J Pediatr Gastroenterol Nutr (2000) 1.63
Genome-wide association and meta-analysis in populations from Starr County, Texas, and Mexico City identify type 2 diabetes susceptibility loci and enrichment for expression quantitative trait loci in top signals. Diabetologia (2011) 1.59
bcl-2 proto-oncogene expression during human T cell development. Evidence for biphasic regulation. J Immunol (1993) 1.57